1. United States Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
Neorich Biopharma Tech Co., Limited

Neorich Biopharma Tech Co., Limited

OOTC:NRBP
0.13
USD
+0.00
(-3.24%)
0.00EPS
3.25TMarket Cap
Neorich Biopharma Tech Co., Limited
OTC:NRBP
(OTC Markets)

Recent

price

0.13

P/E

ratio

- -

div

yld

- -

ROIC.AI

2008
2009
2018
2019
2020
2021
2022
TTM
USD
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.02
-0.26
-0.04
-0.01
-0.03
-0.02
- -
- -
Basic EPS, GAAP
-0.02
-0.23
-0.04
-0.01
-0.01
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.11
-0.04
-0.02
-0.01
-0.03
- -
- -
- -
Book Value per Share
0.11
-0.04
-0.02
-0.01
-0.03
- -
- -
- -
Tangible Book Value per Share
- -
- -
25
74
82
294
404
337
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
-35,807.05
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
-1
-1
-2
-5
-1
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
-32,093.4
Profit Margin (%)
- -
- -
-2
-1
-3
-2
-2
-2
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
-1
-1
-3
-2
-2
-2
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Dec'23
Mar'23
Jun'23
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
455
455
464
Market Capitalization
5,639,036
8,731,411
3,247,727

Working Capital

USD

•

in mil. unless spec.
Dec'23
Mar'23
Jun'23
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
2
Payables & Accruals
1
2
2
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
2,460.07%
7.68%
Free Cash Flow
- -
321.1%
106.99%
Net Income, GAAP
- -
327%
-80.68%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
-0.01
- -
-4.36
-0.02
2022
- -
-5.25
- -
-0.5
- -
2023
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Fiserv, Inc. (NASDAQ:FISV)
Business
Neorich Biopharma Tech Co., Limited operates as a biotechnology and healthcare solutions company focusing on the research, development, commercialization, and distribution of biopharmaceutical products, health supplements, and biomedical technologies. The company’s core product and service portfolio comprises nutritional and dietary supplements, including botanical extracts, immune support formulas, and antioxidant capsules; biomedical wellness and therapeutic formulations designed for metabolic regulation, cellular rejuvenation, and anti-aging care; specialized dermatological and functional skincare treatments; wellness lifestyle goods; and contract research, formulation development, and biotechnology consulting services for enterprise clients. Neorich Biopharma Tech markets and distributes its offerings across multi-channel commercial networks encompassing direct-to-consumer digital commerce platforms, pharmaceutical retail chains, medical institutions, and wholesale distributor networks primarily in the Asia-Pacific region and expanding global territories. In recent developments, the company has undertaken strategic business restructuring to streamline operations, broadened its proprietary nutraceutical and biopharmaceutical product lines, entered into strategic distribution alliances to deepen market penetration across East and Southeast Asia, and accelerated investments in biomedical research and development pipelines focused on advanced bio-active ingredient extraction and health sciences innovations. Founded in 2014 and headquartered in Hong Kong, Neorich Biopharma Tech Co., Limited is publicly traded on the OTC Markets under the ticker symbol NRBP.